Zhongjing Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zhongjing Wang has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Guangda Xiang
Department of Endocrinology, General Hospital of Central Theater Command, Wuluo Road 627, Wuhan, 430070, Hubei Province, China; The First School of Clinical Medicine, Southern Medical University, No.1023, South Shatai Road, Baiyun District, Guangzhou, Guangdong, 510515, China
3 shared publications Sheng Ding
Department of Endocrinology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430014, China
3 shared publicationsDan Wang
Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 shared publications- Gang Yuan
Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 shared publications - Huihui Ren
Department of Endocrinology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 shared publications Jinling Xu
Department of Endocrinology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 shared publications
Latest Publications
- Open Access
- 30 March 2026
- Published by Springer Nature in Molecular Medicine
- Vol. 32 (1) , 46
Correction: Exendin-4 ameliorates tau hyperphosphorylation and cognitive impairment in type 2 diabetes through acting on Wnt/β-catenin/NeuroD1 pathway
- 30 March 2026
- Published by Springer Nature in Molecular Medicine
- Vol. 32 (1) , 46
Open AccessCorrection: Exendin-4 ameliorates tau hyperphosphorylation and cognitive impairment in type 2 diabetes through acting on Wnt/β-catenin/NeuroD1 pathway
- Open Access
- 29 September 2025
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 24 (1) , 1-13
Accelerated biological aging mediates the associations of stress hyperglycemia ratio (SHR) with mortality in type 2 diabetes and obesity (diabesity)
Stress hyperglycemia ratio (SHR) has emerged as an innovative biomarker for stress-induced hyperglycemia and various disease prognosis, yet its relationship with mortality in patients with type 2 diabetes and obesity (termed as diabesity) remains unclear. Accelerated biological aging increases susceptibility to chronic diseases and death. This study sought to examine the association between SHR and mortality in type 2 diabetes and obesity, and also investigate the potential mediating effects of accelerated biological aging in this relationship. We analyzed 4253 individuals with type 2 diabetes and obesity from National Health and Nutritional Examination Survey, with mortality outcomes ascertained through linkage to the National Death Index (NDI). Two accelerated biological aging (PhenoAgeAccel and KDMAgeAccel) were calculated using chronological age and blood biomarkers. The clinical endpoints encompassed all-cause mortality, cardiovascular disease (CVD) mortality, and cancer mortality. We visualized survival differences through Kaplan–Meier methodology. We employed multivariable Cox regression, restricted cubic spline (RCS) analysis, and general linear regression models to evaluate the relationships. Mediation analysis was performed to quantify the accelerated biological aging’ contribution to the SHR-mortality link. Subgroup and sensitivity assessments were applied to verify the robustness of findings. Over a median follow-up period of 110.00 months (interquartile range, 40.00–152.00 months), we recorded 1139 all-cause deaths (26.78%), including 318 CVD deaths (7.48%), and 215 cancer death (5.06%). Kaplan–Meier curves showed higher SHR levels were associated with reduced survival (P < 0.001). After full adjustment for covariates, participants in the highest SHR tertile exhibited significantly elevated hazard ratios (HRs) compared to the reference tertile, with adjusted HRs of 1.32 for all-cause mortality, 1.38 for CVD mortality, and 1.61 for cancer mortality (all P < 0.001). RCS analysis revealed U-shaped relationships for all-cause and CVD mortality, while cancer mortality showed a linear positive correlation with SHR. Both two aging metrics exhibited linear relationships with the mortalities, with SHR positively correlated with KDMAgeAccel and PhenoAgeAccel (β = 5.00 and 1.15, respectively, both P < 0.01). Mediation analysis indicated KDMAgeAccel mediated 10.31%, 12.81%, and 3.65% of SHR’s effects on all-cause, CVD, and cancer mortality, respectively (all P < 0.05), while PhenoAgeAccel showed the suppression effect of SHR on all-cause and CVD mortality, as well as exacerbated SHR’s effect on cancer mortality. These findings remained consistent across all subgroup and sensitivity analyses. Both SHR and accelerated biological aging independently predict higher all-cause, CVD, and cancer mortality in patients with type 2 diabetes and obesity. Furthermore, KDMAgeAccel could significantly mediates these associations, while PhenoAgeAccel could potentially suppress the direct effect of SHR on all-cause and CVD mortality, and exacerbate SHR’s direct effect on cancer mortality. Interventions targeting both stress hyperglycemia and aging-related pathways may reduce mortality risks in patients with type 2 diabetes and obesity.
- 29 September 2025
- Published by Springer Nature in Cardiovascular Diabetology
- Vol. 24 (1) , 1-13
Open AccessAccelerated biological aging mediates the associations of stress hyperglycemia ratio (SHR) with mortality in type 2 diabetes and obesity (diabesity)
Stress hyperglycemia ratio (SHR) has emerged as an innovative biomarker for stress-induced hyperglycemia and various disease prognosis, yet its relationship with mortality in patients with type 2 diabetes and obesity (termed as diabesity) remains unclear. Accelerated biological aging increases susceptibility to chronic diseases and death. This study sought to examine the association between SHR and mortality in type 2 diabetes and obesity, and also investigate the potential mediating effects of accelerated biological aging in this relationship. We analyzed 4253 individuals with type 2 diabetes and obesity from National Health and Nutritional Examination Survey, with mortality outcomes ascertained through linkage to the National Death Index (NDI). Two accelerated biological aging (PhenoAgeAccel and KDMAgeAccel) were calculated using chronological age and blood biomarkers. The clinical endpoints encompassed all-cause mortality, cardiovascular disease (CVD) mortality, and cancer mortality. We visualized survival differences through Kaplan–Meier methodology. We employed multivariable Cox regression, restricted cubic spline (RCS) analysis, and general linear regression models to evaluate the relationships. Mediation analysis was performed to quantify the accelerated biological aging’ contribution to the SHR-mortality link. Subgroup and sensitivity assessments were applied to verify the robustness of findings. Over a median follow-up period of 110.00 months (interquartile range, 40.00–152.00 months), we recorded 1139 all-cause deaths (26.78%), including 318 CVD deaths (7.48%), and 215 cancer death (5.06%). Kaplan–Meier curves showed higher SHR levels were associated with reduced survival (P < 0.001). After full adjustment for covariates, participants in the highest SHR tertile exhibited significantly elevated hazard ratios (HRs) compared to the reference tertile, with adjusted HRs of 1.32 for all-cause mortality, 1.38 for CVD mortality, and 1.61 for cancer mortality (all P < 0.001). RCS analysis revealed U-shaped relationships for all-cause and CVD mortality, while cancer mortality showed a linear positive correlation with SHR. Both two aging metrics exhibited linear relationships with the mortalities, with SHR positively correlated with KDMAgeAccel and PhenoAgeAccel (β = 5.00 and 1.15, respectively, both P < 0.01). Mediation analysis indicated KDMAgeAccel mediated 10.31%, 12.81%, and 3.65% of SHR’s effects on all-cause, CVD, and cancer mortality, respectively (all P < 0.05), while PhenoAgeAccel showed the suppression effect of SHR on all-cause and CVD mortality, as well as exacerbated SHR’s effect on cancer mortality. These findings remained consistent across all subgroup and sensitivity analyses. Both SHR and accelerated biological aging independently predict higher all-cause, CVD, and cancer mortality in patients with type 2 diabetes and obesity. Furthermore, KDMAgeAccel could significantly mediates these associations, while PhenoAgeAccel could potentially suppress the direct effect of SHR on all-cause and CVD mortality, and exacerbate SHR’s direct effect on cancer mortality. Interventions targeting both stress hyperglycemia and aging-related pathways may reduce mortality risks in patients with type 2 diabetes and obesity.
- 27 February 2025
- Published by Springer Nature in Diabetologia
- Vol. 68 (5) , 1057-1075
Brown adipose tissue alleviates podocyte apoptosis through NRG4 in a male mouse model of diabetic kidney disease
Aims/hypothesis Brown adipose tissue (BAT) consumes excess energy through heat production by uncoupling protein 1 (UCP1) to regulate the metabolic profile, but the UCP1-independent mechanisms of BAT, such as in endocrine function, are largely unknown. Our previous study showed that BAT-derived neuregulin 4 (NRG4) displays anti-atherosclerotic properties. Thus, we hypothesised that BAT could regulate diabetic nephropathy, a diabetic microvascular complication, via NRG4. Methods To investigate the influence of NRG4 from BAT on podocyte apoptosis, both loss- and gain-of-function approaches were used in in vivo experiments. Diabetic nephropathy models were created using BAT-specific Nrg4-knockout (BKO) mice, global Nrg4-knockout (KO) mice and wild-type (WT) mice. In in vitro studies, podocytes (MPC5) were exposed to glucose and recombinant NRG4 (rNrg4). Additionally, brown adipocytes were co-cultured with MPC5 podocytes using a transwell system. The expression levels of proteins associated with podocyte apoptosis and signalling pathways were measured. Results BAT-specific NRG4 deficiency aggravated podocyte apoptosis (increased by 47.46%) and increased the urinary albumin/creatinine ratio (increased by 41.71%), decreased nephrin expression and increased desmin expression. As expected, these changes were reversed by NRG4 replenishment using adeno-associated virus–NRG4 interscapular BAT injection and BAT transplantation assays in KO mice. Additionally, co-culture experiments demonstrated that brown adipocytes from WT mice could alleviate high-glucose-induced podocyte apoptosis. In in vitro experiments, recombinant NRG4 inhibited high-glucose-induced podocyte apoptosis. Mechanistically, the Akt–glycogen synthase kinase 3 β (GSK-3β) pathway is crucial for the protection that BAT-derived NRG4 provides to podocytes in diabetic nephropathy. Conclusions/interpretation Our data show that BAT had a protective effect on podocyte apoptosis in diabetic nephropathy through BAT-derived NRG4, and the Akt–GSK‑3β signalling pathway may mediate the inhibition of BAT-derived NRG4 on podocyte apoptosis in diabetic nephropathy. Graphical Abstract
- 27 February 2025
- Published by Springer Nature in Diabetologia
- Vol. 68 (5) , 1057-1075
Brown adipose tissue alleviates podocyte apoptosis through NRG4 in a male mouse model of diabetic kidney disease
Aims/hypothesis Brown adipose tissue (BAT) consumes excess energy through heat production by uncoupling protein 1 (UCP1) to regulate the metabolic profile, but the UCP1-independent mechanisms of BAT, such as in endocrine function, are largely unknown. Our previous study showed that BAT-derived neuregulin 4 (NRG4) displays anti-atherosclerotic properties. Thus, we hypothesised that BAT could regulate diabetic nephropathy, a diabetic microvascular complication, via NRG4. Methods To investigate the influence of NRG4 from BAT on podocyte apoptosis, both loss- and gain-of-function approaches were used in in vivo experiments. Diabetic nephropathy models were created using BAT-specific Nrg4-knockout (BKO) mice, global Nrg4-knockout (KO) mice and wild-type (WT) mice. In in vitro studies, podocytes (MPC5) were exposed to glucose and recombinant NRG4 (rNrg4). Additionally, brown adipocytes were co-cultured with MPC5 podocytes using a transwell system. The expression levels of proteins associated with podocyte apoptosis and signalling pathways were measured. Results BAT-specific NRG4 deficiency aggravated podocyte apoptosis (increased by 47.46%) and increased the urinary albumin/creatinine ratio (increased by 41.71%), decreased nephrin expression and increased desmin expression. As expected, these changes were reversed by NRG4 replenishment using adeno-associated virus–NRG4 interscapular BAT injection and BAT transplantation assays in KO mice. Additionally, co-culture experiments demonstrated that brown adipocytes from WT mice could alleviate high-glucose-induced podocyte apoptosis. In in vitro experiments, recombinant NRG4 inhibited high-glucose-induced podocyte apoptosis. Mechanistically, the Akt–glycogen synthase kinase 3 β (GSK-3β) pathway is crucial for the protection that BAT-derived NRG4 provides to podocytes in diabetic nephropathy. Conclusions/interpretation Our data show that BAT had a protective effect on podocyte apoptosis in diabetic nephropathy through BAT-derived NRG4, and the Akt–GSK‑3β signalling pathway may mediate the inhibition of BAT-derived NRG4 on podocyte apoptosis in diabetic nephropathy. Graphical Abstract
- Open Access
- 30 August 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1434580
Neutrophil-to-lymphocyte ratio in type 2 diabetes patients combined with Lower Extremity Peripheral Artery Disease
Objective: This study explored the utility of NLR (neutrophil-to-lymphocyte ratio) as a marker to predict Lower Extremity Peripheral Artery Disease (PAD) in the Chinese population, as well as to assess its consistency and diagnostic value with digital subtraction angiography.Methods: Patients were distributed into three groups according to the angiography in lower limb arterial: group L1, plaque with no stenosis; group L2, plaque with luminal stenosis and group L3, total vascular occlusion. Changes in the neutrophil-to-lymphocyte ratio were documented and compared among groups.Results: Compared to group L1, NLR was significantly increased in L2 (1.76 vs 2.35, p=0.037) and L3 (1.76 vs 3.60, p<0.001), with a gradual decrease in ABI (Ankle-Brachial Index, 1.11 vs 1.02 vs 0.94, p<0.001). Those older patients with higher prevalence of hypertension (p=0.002), obesity (p=0.032), or reduced high-density lipoprotein cholesterol (p=0.020) were more likely to develop PAD; higher glycosylated hemoglobin (p=0.045), low-density lipoprotein cholesterol (p=0.006), and systolic blood pressure (p<0.001) levels led to a greater tendency to suffer stenosis or even occlusion; the probability of severe stenosis (>70%) increased to 2.075 times for every 1 increase in NLR, while it was 46.8% for every 0.1 increase in ABI. The optimal NLR cut-off value to predict severe stenosis in PAD was 2.73. Receiver operating characteristic curve analysis of the inflammatory biomarkers and severe stenosis prediction displayed an area under the curve of 0.81.Conclusion: NLR could serve as a new noninvasive and accurate marker in predicting PAD.
- 30 August 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1434580
Open AccessNeutrophil-to-lymphocyte ratio in type 2 diabetes patients combined with Lower Extremity Peripheral Artery Disease
Objective: This study explored the utility of NLR (neutrophil-to-lymphocyte ratio) as a marker to predict Lower Extremity Peripheral Artery Disease (PAD) in the Chinese population, as well as to assess its consistency and diagnostic value with digital subtraction angiography.Methods: Patients were distributed into three groups according to the angiography in lower limb arterial: group L1, plaque with no stenosis; group L2, plaque with luminal stenosis and group L3, total vascular occlusion. Changes in the neutrophil-to-lymphocyte ratio were documented and compared among groups.Results: Compared to group L1, NLR was significantly increased in L2 (1.76 vs 2.35, p=0.037) and L3 (1.76 vs 3.60, p<0.001), with a gradual decrease in ABI (Ankle-Brachial Index, 1.11 vs 1.02 vs 0.94, p<0.001). Those older patients with higher prevalence of hypertension (p=0.002), obesity (p=0.032), or reduced high-density lipoprotein cholesterol (p=0.020) were more likely to develop PAD; higher glycosylated hemoglobin (p=0.045), low-density lipoprotein cholesterol (p=0.006), and systolic blood pressure (p<0.001) levels led to a greater tendency to suffer stenosis or even occlusion; the probability of severe stenosis (>70%) increased to 2.075 times for every 1 increase in NLR, while it was 46.8% for every 0.1 increase in ABI. The optimal NLR cut-off value to predict severe stenosis in PAD was 2.73. Receiver operating characteristic curve analysis of the inflammatory biomarkers and severe stenosis prediction displayed an area under the curve of 0.81.Conclusion: NLR could serve as a new noninvasive and accurate marker in predicting PAD.
- Open Access
- 1 February 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (2) , e8458
The clinical and genetic characteristics of maternally inherited diabetes and deafness ( MIDD ) with mitochondrial m. 3243A > G mutation: A 10‐year follow‐up observation study and literature review
Key Clinical Message: Maternally inherited diabetes and deafness (MIDD) is often caused by the m.3243A > G mutation in mitochondrial DNA. Unfortunately, the characteristics of MIDD, especially long‐term outcomes and heteroplasmic changes, have not been well described previously. The purpose of this study was to describe the clinical and genetic features of a family with MIDD after 10 years of follow‐up.A 33‐year‐old male patient with typical characteristics of MIDD, including early‐onset diabetes, deafness, and low body mass index, was admitted to our department. Further investigation revealed that the vast majority of his maternal relatives suffered from diabetes with or without deafness. A detailed family history was then requested from the patient and a pedigree was constructed. The patient suspected of MIDD was screened for mutations using whole mitochondrial DNA sequencing. Candidate pathogenic variants were then validated in other family members through Sanger sequencing. The patient was diagnosed with MIDD, with inherited m.3243A > G mutation in the mitochondrially encoded tRNA leucine 1 (MT‐TL1) gene, after 10 years of symptom onset. The patient was then treated with insulin and coenzyme Q10 to improve mitochondrial function. During the follow‐up period, his fasting blood glucose and HbA1c levels were improved and the incidence of diabetic ketoacidosis was significantly reduced. Our findings indicate that whole mitochondrial DNA sequencing should be considered for patients suspected of MIDD to improve the efficiency of diagnosis and prognosis.
- 1 February 2024
- Published by Wiley in Clinical Case Reports
- Vol. 12 (2) , e8458
Open AccessThe clinical and genetic characteristics of maternally inherited diabetes and deafness ( MIDD ) with mitochondrial m. 3243A > G mutation: A 10‐year follow‐up observation study and literature review
Key Clinical Message: Maternally inherited diabetes and deafness (MIDD) is often caused by the m.3243A > G mutation in mitochondrial DNA. Unfortunately, the characteristics of MIDD, especially long‐term outcomes and heteroplasmic changes, have not been well described previously. The purpose of this study was to describe the clinical and genetic features of a family with MIDD after 10 years of follow‐up.A 33‐year‐old male patient with typical characteristics of MIDD, including early‐onset diabetes, deafness, and low body mass index, was admitted to our department. Further investigation revealed that the vast majority of his maternal relatives suffered from diabetes with or without deafness. A detailed family history was then requested from the patient and a pedigree was constructed. The patient suspected of MIDD was screened for mutations using whole mitochondrial DNA sequencing. Candidate pathogenic variants were then validated in other family members through Sanger sequencing. The patient was diagnosed with MIDD, with inherited m.3243A > G mutation in the mitochondrially encoded tRNA leucine 1 (MT‐TL1) gene, after 10 years of symptom onset. The patient was then treated with insulin and coenzyme Q10 to improve mitochondrial function. During the follow‐up period, his fasting blood glucose and HbA1c levels were improved and the incidence of diabetic ketoacidosis was significantly reduced. Our findings indicate that whole mitochondrial DNA sequencing should be considered for patients suspected of MIDD to improve the efficiency of diagnosis and prognosis.
- 30 December 2023
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 76, 77-85
Myeloid-derived growth factor and its effects on cardiovascular and metabolic diseases
- 30 December 2023
- Published by Elsevier in Cytokine & Growth Factor Reviews
- Vol. 76, 77-85
Myeloid-derived growth factor and its effects on cardiovascular and metabolic diseases
- Open Access
- 4 September 2023
- Published by Springer Nature in Molecular Medicine
- Vol. 29 (1) , 1-20
Exendin-4 ameliorates tau hyperphosphorylation and cognitive impairment in type 2 diabetes through acting on Wnt/β-catenin/NeuroD1 pathway
Background: Type 2 diabetes (T2D) is an independent risk factor for Alzheimer's disease (AD). Exendin-4 (Ex-4), a widely used glucagon-like peptide-1 receptor agonist drug in the treatment of T2D, has been demonstrated the therapeutic effects on diabetic encephalopathy (DE). Especially, the Ex-4 ameliorates the tau hyperphosphorylation and cognitive impairment in DE. And these crucial alterations are also important bridge between T2D and AD. However, its unique mechanism is unclear. Methods: The db/db mice, high-fat-diet (HFD) / streptozotocin (STZ)—induced diabetic (HF-diabetic) mice, and high-glucose-damaged (HGD) HT-22 hippocampal cells were enrolled to examine the effects of Ex-4 on AD-like changes in T2D. The Novel object recognition test (NORT) and Morris water maze test (MWMT) were conducted to evaluate the cognitive impairment. The Dickkopf-1 (DKK1) was employed to weaken the activation of the Wnt/β-catenin pathway to explore the mechanism of Ex-4 in protecting the brain functions. The JASPAR was based to predict the interaction between NeuroD1 and the promoter region of Ins2 . Moreover, the chromatin immunoprecipitation coupled with quantitative polymerase chain reaction (ChIP-qPCR) and luciferase reporter assays were performed. Results: Ex-4 alleviated the tau hyperphosphorylation, increased the brain-derived insulin, and improved the PI3K/AKT/GSK3-β signalling in db/db mice, HF-diabetic mice, and HGD HT-22 hippocampal neuronal cells. The NORT and MWMT indicated that Ex-4 alleviated the learning and memory deficits in HF-diabetic mice. The inhibitor Dickkopf-1 (DKK1) of the Wnt/β-catenin pathway significantly blocked the protective effects of Ex-4. Regarding further molecular mechanisms, NeuroD1 was affected by Ex-4 in vivo and in vitro, and the knockdown or overexpression of NeuroD1 suggested its crucial role in promoting the brain insulin by Ex-4. Meanwhile, the ChIP‒qPCR and luciferase reporter assays confirmed the combination between NeuroD1 and the promoter region of the insulin-encoding gene Ins2 . And this interaction could be promoted by Ex-4. Conclusions: Our study proposes that Ex-4 alleviates tau hyperphosphorylation and cognitive dysfunction by increasing Ins2 -derived brain insulin through the Wnt/β-catenin/NeuroD1 signaling in T2D. And its also show new lights on part of the progress and mechanism on treatment targets for the DE in T2D.
- 4 September 2023
- Published by Springer Nature in Molecular Medicine
- Vol. 29 (1) , 1-20
Open AccessExendin-4 ameliorates tau hyperphosphorylation and cognitive impairment in type 2 diabetes through acting on Wnt/β-catenin/NeuroD1 pathway
Background: Type 2 diabetes (T2D) is an independent risk factor for Alzheimer's disease (AD). Exendin-4 (Ex-4), a widely used glucagon-like peptide-1 receptor agonist drug in the treatment of T2D, has been demonstrated the therapeutic effects on diabetic encephalopathy (DE). Especially, the Ex-4 ameliorates the tau hyperphosphorylation and cognitive impairment in DE. And these crucial alterations are also important bridge between T2D and AD. However, its unique mechanism is unclear. Methods: The db/db mice, high-fat-diet (HFD) / streptozotocin (STZ)—induced diabetic (HF-diabetic) mice, and high-glucose-damaged (HGD) HT-22 hippocampal cells were enrolled to examine the effects of Ex-4 on AD-like changes in T2D. The Novel object recognition test (NORT) and Morris water maze test (MWMT) were conducted to evaluate the cognitive impairment. The Dickkopf-1 (DKK1) was employed to weaken the activation of the Wnt/β-catenin pathway to explore the mechanism of Ex-4 in protecting the brain functions. The JASPAR was based to predict the interaction between NeuroD1 and the promoter region of Ins2 . Moreover, the chromatin immunoprecipitation coupled with quantitative polymerase chain reaction (ChIP-qPCR) and luciferase reporter assays were performed. Results: Ex-4 alleviated the tau hyperphosphorylation, increased the brain-derived insulin, and improved the PI3K/AKT/GSK3-β signalling in db/db mice, HF-diabetic mice, and HGD HT-22 hippocampal neuronal cells. The NORT and MWMT indicated that Ex-4 alleviated the learning and memory deficits in HF-diabetic mice. The inhibitor Dickkopf-1 (DKK1) of the Wnt/β-catenin pathway significantly blocked the protective effects of Ex-4. Regarding further molecular mechanisms, NeuroD1 was affected by Ex-4 in vivo and in vitro, and the knockdown or overexpression of NeuroD1 suggested its crucial role in promoting the brain insulin by Ex-4. Meanwhile, the ChIP‒qPCR and luciferase reporter assays confirmed the combination between NeuroD1 and the promoter region of the insulin-encoding gene Ins2 . And this interaction could be promoted by Ex-4. Conclusions: Our study proposes that Ex-4 alleviates tau hyperphosphorylation and cognitive dysfunction by increasing Ins2 -derived brain insulin through the Wnt/β-catenin/NeuroD1 signaling in T2D. And its also show new lights on part of the progress and mechanism on treatment targets for the DE in T2D.
- Open Access
- 20 March 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (3) , 556
Diagnostic Value of the Combined Measurement of Serum HCY and NRG4 in Type 2 Diabetes Mellitus with Early Complicating Diabetic Nephropathy
Purpose: This study aimed to investigate the value of combined detection of HCY and NRG4 in the diagnosis of early diabetic kidney disease (DKD) and to explore the association between the ratio of HCY/NRG4 and DKD. Methods: A total of 140 diabetic patients and 43 healthy people were prospectively enrolled. The plasma HCY level, NRG4 level and HCY/NRG4 of them were measured to compare their differences and analyze the correlation with DKD. The independent influencing factors of patients with DKD were screened, and the nomograph of DKD occurrence was constructed. Results: The levels of HCY and HCY/NRG4 in diabetic patients were significantly increased, while the level of NRG4 was significantly decreased (p < 0.01). The AUCs of HCY/NRG4 predicted for DKD were 0.961. HCY/NRG4 and the course of DM were independent risk factors for DKD. A predictive nomograph of DKD was constructed, and decision curve analysis (DCA) showed good clinical application value. HCY/NRG4 was positively correlated with Scr, UACR, TG, UA, BUN, TCHOL and LDL and negatively correlated with eGFR and HDL (p < 0.05). Conclusions: The level of HCY and NRG4 is closely related to the severity of DM, and combined detection of HCY/NRG4 can identify patients with DKD at an early stage.
- 20 March 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (3) , 556
Open AccessDiagnostic Value of the Combined Measurement of Serum HCY and NRG4 in Type 2 Diabetes Mellitus with Early Complicating Diabetic Nephropathy
Purpose: This study aimed to investigate the value of combined detection of HCY and NRG4 in the diagnosis of early diabetic kidney disease (DKD) and to explore the association between the ratio of HCY/NRG4 and DKD. Methods: A total of 140 diabetic patients and 43 healthy people were prospectively enrolled. The plasma HCY level, NRG4 level and HCY/NRG4 of them were measured to compare their differences and analyze the correlation with DKD. The independent influencing factors of patients with DKD were screened, and the nomograph of DKD occurrence was constructed. Results: The levels of HCY and HCY/NRG4 in diabetic patients were significantly increased, while the level of NRG4 was significantly decreased (p < 0.01). The AUCs of HCY/NRG4 predicted for DKD were 0.961. HCY/NRG4 and the course of DM were independent risk factors for DKD. A predictive nomograph of DKD was constructed, and decision curve analysis (DCA) showed good clinical application value. HCY/NRG4 was positively correlated with Scr, UACR, TG, UA, BUN, TCHOL and LDL and negatively correlated with eGFR and HDL (p < 0.05). Conclusions: The level of HCY and NRG4 is closely related to the severity of DM, and combined detection of HCY/NRG4 can identify patients with DKD at an early stage.
- Open Access
- 1 February 2022
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 10 (4) , 167
Improving the clinical ability and quality of endocrinology department with diagnosis-related groups tool
Improving the clinical ability and quality of endocrinology department with diagnosis-related groups tool Sheng Ding, Xiaowan Jiang, Yuming Zheng, Tao Feng, Hong Mao, Zhi Chen, Wei Cai, Zhongjing Wang
- 1 February 2022
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 10 (4) , 167
Open AccessImproving the clinical ability and quality of endocrinology department with diagnosis-related groups tool
Improving the clinical ability and quality of endocrinology department with diagnosis-related groups tool Sheng Ding, Xiaowan Jiang, Yuming Zheng, Tao Feng, Hong Mao, Zhi Chen, Wei Cai, Zhongjing Wang
- Open Access
- 18 May 2021
- Published by Wiley in Stem Cells International
- Vol. 2021, 1-8
China’s Stem Cell Research and Knowledge Levels of Medical Practitioners and Students
Over the last few decades, China has greatly expanded its scope of stem cell research, generating various scientific advances and medical applications. However, knowledge of the extent and characteristics of domestic stem cell development, particularly medical workers’ opinions, is lacking. This study’s purposes were to analyze the growth trends of China’s stem cell community and identify the knowledge and attitudes held by Chinese medical workers regarding stem cell research. We found that there are currently 13 high-quality stem cell research centers with more than 400 PhD-level researchers across Mainland China. These centers feature many high-caliber scientists from the stem cell research community. From 1997 through 2019, the National Natural Science Foundation of China allocated roughly $576 million to 8,050 stem cell programs at Chinese universities and research institutions. China’s annual publications on stem cells increased from less than 0.6% of the world’s total stem cell publications in 1999 to more than 14.1% in 2014. Our survey also revealed that most participants held positive attitudes toward stem cell research, supported further funding, and had high general awareness about stem cells.
- 18 May 2021
- Published by Wiley in Stem Cells International
- Vol. 2021, 1-8
Open AccessChina’s Stem Cell Research and Knowledge Levels of Medical Practitioners and Students
Over the last few decades, China has greatly expanded its scope of stem cell research, generating various scientific advances and medical applications. However, knowledge of the extent and characteristics of domestic stem cell development, particularly medical workers’ opinions, is lacking. This study’s purposes were to analyze the growth trends of China’s stem cell community and identify the knowledge and attitudes held by Chinese medical workers regarding stem cell research. We found that there are currently 13 high-quality stem cell research centers with more than 400 PhD-level researchers across Mainland China. These centers feature many high-caliber scientists from the stem cell research community. From 1997 through 2019, the National Natural Science Foundation of China allocated roughly $576 million to 8,050 stem cell programs at Chinese universities and research institutions. China’s annual publications on stem cells increased from less than 0.6% of the world’s total stem cell publications in 1999 to more than 14.1% in 2014. Our survey also revealed that most participants held positive attitudes toward stem cell research, supported further funding, and had high general awareness about stem cells.